Last updated: 2023-11-16

Unique indications: 1014

Unique indications - of which genetic insight: 769

Unique targets: 2270

Unique T-I: 19403

Unique D-T-I: 46015

Approved | Unique targets: 450

Approved | Unique indications: 474

Approved | Unique T-I: 1816

Historical | Unique targets: 1923

Historical | Unique indications: 793

Historical | Unique T-I: 11730

Active | Unique targets: 1304

Active | Unique indications: 683

Active | Unique T-I: 5991

Merged sim ≥0.8 | Unique targets: 705

Merged sim ≥0.8 | Unique indications: 368

Merged sim ≥0.8 | Unique T-I (all): 1592

Merged sim ≥0.8 | Unique T-I (meeting default criteria): 600

Merged sim ≥0.8 | Unique T-I-A: 2187

Assocs | Unique T-A: 81939

Assocs | OTG | Unique T-A (all): 172046

Assocs | OTG | Unique T-A (L2G >= 0.5): 66203

Assocs | OMIM | Unique T-A: 4510

Assocs | PICCOLO | Unique T-A: 8186

Assocs | Genebass | Unique T-A: 4313

Assocs | intOGen | Unique T-A: 2506

Pharmaprojects | MeSH missing from sim matrix: 7/982

Pharmaprojects | MeSH present in sim matrix: 975/982

Pharmaprojects | proportion of unique MeSH in sim matrix: 99.287%

Pharmaprojects | proportion assoc rows in sim matrix: 99.948%

Assocs | MeSH missing from sim matrix: 2/2262

Assocs | MeSH present in sim matrix: 2260/2262

Assocs | proportion of unique MeSH in sim matrix: 99.912%

Assocs | proportion assoc rows in sim matrix: 99.999%

Logit model launched ~ assoc_year: beta = -0.014, P = 0.62

Logit model launched ~ gene_count: beta = 0.00048, P = 0.034

Enrichment of top 3 highest-RS therapy areas for gene_count >= 100: OR = 3.1, P = 0.000031

Logit model launched ~ abs_beta: beta = -0.0016, P = 0.97

Logit model launched ~ abs_or: beta = -0.033, P = 0.63

Logit model launched ~ lead_maf: beta = 1.4, P = 0.094

Combined P(G) for Launched T-I: 12.5%

Combined P(G) for all active clinical T-I: 6.3% (207/3275)

Combined P(G) for all historical clinical T-I: 5.1% (383/7582)

Indications with 0 supported genes: 179

Genetic support for launched T-I from OTG was retrospective (min_assoc_year >= year_launch) in 18/38 (47%) instances

CMH test on I-Launched RS values across 17 therapy areas: P = 1.0e-15

For all time, of 517 launched targets, the 74 with ≥10 launched indications account for 1243 of 2492 launched indications (50%)

Since 2000 only, of 450 launched targets, the 42 with ≥10 launched indications account for 713 of 1806 launched indications (39%)

Spearman's correlation n_launched_indic vs. meansim across targets: rho = -0.721, P = 4.4e-84

Logit model gensup ~ ipert: beta = -0.0483, P = 6.5e-07

Logit model gensup ~ ipert without 1-indication targets: beta = -0.0334, P = 7.7e-04

Logit model gensup ~ meansim: beta = 1.38, P = 1.9e-05

Logit model gensup ~ meansim without 1-indication targets: beta = -0.615, P = 3.0e-01

Weighted Pearson correlation across areas, poss_supp_gi vs. rs: rho= 0.6, P = 1.00e-02

Spearman correlation n_launched_indic vs. mean_sim: rho= -0.72, P = 0.0000000000000000000000000000000000000000000000000000000000000000000000000000000000044

Weighted Pearson correlation across areas, mean_sim vs. rs: rho= 0.7, P = 0.002

Weighted Pearson correlation across areas, indic per target vs. rs: rho= -0.59, P = 0.012

Confounding between therapy area and year of discovery among OTG GWAS Catalog-supported T-I pairs: KW test P = 7.8e-07, Chi Square test P = 4.1e-10

Confounding between therapy area and gene count among OTG GWAS Catalog-supported T-I pairs: KW test P = 3.7e-24, Chi Square test P = 4.3e-33

Confounding between therapy area and beta among OTG GWAS Catalog-supported T-I pairs: KW test P = 1.7e-04, Chi Square test P = 2.8e-04

Confounding between therapy area and OR among OTG GWAS Catalog-supported T-I pairs: KW test P = 3.8e-06, Chi Square test P = 4.9e-10

Confounding between therapy area and MAF among OTG GWAS Catalog-supported T-I pairs: KW test P = 4.6e-02, Chi Square test P = 1.4e-02

Confounding between therapy area and GWAS source: Chi Square test P = 6.2e-04

Weighted Pearson's correlation P(G) vs P(S) across areas: rho = 0.509, P = 3.7e-02

Weighted Pearson's correlation P(S) vs RS across areas: rho = 0.0959, P = 7.1e-01

Weighted Pearson's correlation P(G) vs RS across areas: rho = 0.701, P = 1.7e-03

Overall RS from Nelson 2015: 2.02 vs. current study: 2.08

T-I in Phase I-III with genetic support: 383/7582 historical vs. 207/3275 active. OR = 1.3, P = 0.0085

Fisher's test for enrichment of genetically supported T-I pairs among those developed: OR= 12.4, P = 0.00e+00

Space of possible T-I pairs: 19338 genes times 769 indications with genetic insight = 14,870,922 T-I pairs

Number of possible T-I pairs with genetic support: 101954 = 0.69%

Number of clinically developed T-I pairs: 10334

Number of clinically developed T-I pairs with genetic support: 801 = 0.79% of possible / 7.75% of Phase I+

After removing heavy hitters and restricting to most similar indications, the number of possible T-I pairs with genetic support: 34190 = 0.23%

Number of clinically developed T-I pairs with genetic support: 527 = 1.54%

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, 69% (669/972) have been developed only for unsupported indications.

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, 7% (67/972) have been developed only for supported indications.

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, 24% (236/972) have been developed for both.

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, there were 7394 unsupported indications and 527 supported indications pursued, a ratio of 14.0

Of launched targets with both ≥1 supported indication and ≥1 Phase I+ indication, there were 4487 unsupported indications and 340 supported indications pursued, a ratio of 13.2

Of non-launched targets with both ≥1 supported indication and ≥1 Phase I+ indication, there were 2907 unsupported indications and 187 supported indications pursued, a ratio of 15.5

Fisher test for difference between these ratios: OR=1.2, P=0.09.

Ordinal logistic model for drug-indication advancement: genetic support beta= 0.55, P = 2.54e-55

